Author: Editor

Andrew Wei, MBBS, Ph.D. Alfred Hospital and Monash University U.S. Food and Drug Administration Approves Onureg® (azacitidine tablets), a New Oral Therapy, as Continued Treatment for Adults in First Remission with Acute Myeloid Leukemia. The approval is focused on the findings of the seminal phase 3 QUAZAR ® AML-001 trial, in which Onureg treatment resulted in a statistically significant and clinically significant overall survival (OS) improvement, the primary endpoint of the research, of almost 10 months compared to placebo. Median OS from randomization was greater than two years (24.7 months; 95 % confidence interval [CI]: 18.7 to 30.5) in patients…

Catherine Haring, MD & Paul Swiecicki, MD from University of Michigan Medical School discuss an ASCO 2020 abstract entitled HPV ctDNA analysis in unresectable recurrent/metastatic oropharyngeal cancer Bottom line: The incidence of related human papillomavirus (HPV+) oropharyngeal cancer (OPC) is growing. While HPV + portents enhanced prognosis, survival remains low for patients with unresectable recurrent / metastatic (R / M) OPC. Extant data indicate that HPV ctDNA levels correlate in the primary setting with disease burden and treatment outcomes in patients with HPV + OPC, although there is little data in the metastatic setting. Objective: To establish a highly precise…

Ralph Zinner, MD University of Kentucky discusses an ASCO 2020 abstract entitled Neoadjuvant nivolumab (N) plus weekly carboplatin (C) and paclitaxel (P) in resectable locally advanced head and neck cancer Bottom line: Patients (pts) with resectable locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) are at high risk for recurrence, despite normal multimodality treatment. Improved overall survival of pts with pathologic complete response (pCR) or significant pathologic response (MPR) to neoadjuvant chemotherapy. In conjunction with platinum-based chemotherapy, PD-1 checkpoint inhibitors are approved for 1st-line treatment of recurrent / metastatic SCCHN. We believe that, relative to historical…

Manisha H Shah, MD of The James Ohio State University Comprehensive Cancer Center discusses the Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. BACKGROUND  RET mutations occur in 70 percent of cancers of the medullary thyroid and RET fusions seldom occur in other thyroid cancers. The effectiveness and safety of the selective RET inhibition is uncertain in patients with RET-altered thyroid cancers. FOR METHODS In a phase 1-2 trial of selpercatinib, patients with RET-mutant medullary thyroid cancer with or without prior treatment with vandetanib or cabozantinib, as well as those with previously treated RET fusion-positive thyroid cancer, were enrolled. As decided…

Jan Ole Kemnade, MD, Ph.D. from Baylor College of Medicine discusses and ASCO 2020 abstract entitled Computational discovery of non-mutational tumor-restricted antigens reveals evidence of immunoediting in head and neck squamous cell carcinoma Bottom line: We previously identified 107 tumor antigens (EbTAgs), defined as genes with negligible expression in healthy tissue and cancer overexpression. EbTAgs present novel adaptive anti-tumor immune response targets and display signs of immunoediting in highly immune oral cavity infiltrated tumors. The EbTAgs expression was contrasted between four HNSCC subtypes in the sense of tumor immune infiltration: oral cavity (OC), HPV+ oropharyngeal (HPV+OP), HPV- oropharyngeal (HPV-OP), and…

Rebecca Christian Arend, MD at University of Alabama discusses an abstract from ASCO 2020 Clinical trial in progress: Pivotal study of VB-111 combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018) Bottom line: Ofranergene obadenovec (VB-111) is a focused, dual-mechanism anti-cancer gene therapy: a broad antiangiogenic effect and the activation of a tumor-directed viral immune response. In a phase II trial of platinum-resistant VB-111 ovarian cancer in conjunction with weekly paclitaxel, the response rate (RR) of CA-125 was 58% and the median overall survival (OS) was 498 days, compared to the subtherapeutic dose of 172.5 days…

Michelle Echevarria, MD from Moffitt Cancer Center discusses an ASCO 2020 Phase I dose escalation of stereotactic body radiation therapy and concurrent cisplatin for re-irradiation of unresectable, recurrent head and neck squamous cell carcinoma Bottom line: A stereotactic body radiation therapy (SBRT) has become an appealing choice for patients with unresectable, previously radiated, locoregionally recurrent head and neck cancer. The intrinsic radiation tolerance of these recurrent cancers can be overcome by the use of high regular doses of radiotherapy. The addition of chemotherapy to radiotherapy is usually prescribed as a radiosensitizer, considering the resistant and advanced nature of many of…

Kedar Kirtane, MD from Moffitt Cancer Center discusses an ASCO 2020 abstract entitled Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of phase II study Bottom line: Although there is efficacy of anti-programmed death-1 (anti-PD-1) inhibitors, only some patients (pts) with R / M HNSCC gain substantial clinical benefits. In patients who had progressed to at least one previous treatment for their R / M HNSCC, the research was designed to evaluate the 1-year overall survival (OS) rate of concurrent CTX and NIVO. Approaches: Pts were handled…

Kathleen N. Moore, MD from OU Medicine discusses an ASCO 2020 abstract entitled MIRASOL (GOG 3045/ENGOT OV-55): A randomized, open-label, phase III study of mirvetuximab soravtansine versus investigator’s choice of chemotherapy in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FRα) expression. Bottom line: Elevated expression of FRα is a feature of many solid tumors, including epithelial ovarian cancer (EOC) and thus provides an attractive candidate for targeted therapeutic approaches. Mirvetuximab soravtansine is an antibody-drug conjugate (ADC) comprising a FRα-binding antibody, cleavable linker, and the maytansinoid DM4, a potent tubulin-targeting agent that has shown consistent…

Denise Manon Langabeer, MBA, Ph.D. of MD Anderson gives an overview from ASCO 2020 the abstract entitled Are symptoms distinguishable in ovarian cancer? A nested case-control study of insurance claims. Background: Step III and IV disease was diagnosed in over 60 percent of ovarian cancer cases. A common screening procedure for ovarian cancer is not funded by the US healthcare system. Our aim was to decide if some signs are distinguishable between women diagnosed with ovarian cancer and women without ovarian cancer, based on ICD-9 categories. Approaches: In order to endorse a nested case-control study of health insurance claims from…

Ben George, MD from Froedtert & Medical College discusses an ASCO 2020 abstract entitied A phase I, first-in-human, open-label, dose‑escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP‑1287 administered daily to patients with advanced solid tumors Context: TP-1287 is an alvocidib, cyclin-dependent kinase 9 (CDK9) inhibitor, orally bioavailable phosphate prodrug. TP-1287 demonstrates powerful inhibition of CDK9 and intracellular kinases. Inhibition of CDK9 contributes to downregulation of the BCL-2 family member, MCL-1, which in turn inhibits tumor development of prostate , breast, and lung carcinomas in preclinical animal models. Approaches: This is a Phase 1 multicenter dose escalation study in patients…

Shannon N. Westin, M.D., M.P.H., F.A.C.O.G. from MD Anderson discusses an ASCO 2020 abstract entitled – DUO-E/GOG-3041/ENGOT-EN10: a randomized phase III trial of first-line carboplatin (carb) and paclitaxel (pac) in combination with durvalumab (durva), followed by maintenance durva with or without olaparib (ola), in patients (pts) with newly diagnosed (nd) advanced or recurrent endometrial cancer (EC) Context: Progress in EC care that offers progression-free survival (PFS) and overall survival (OS) benefits is a high unmet need. EC tumors are susceptible (Pectasides et al. Gynecol Oncol 2008) to carb / pac. Poly(ADP-ribose) polymerase inhibitor (PARPi) ola (with or without bevacizumab) maintenance…

Mansoor Raza Mirza, MD from Region Hovedstaden discusses an abstract from ASCO 2020 entitled Final survival analysis of Smita Bhatia, MD of UAB discusses an article in the Journal of Clinical Oncology entitled Total Body Irradiation and Risk of Breast Cancer After Blood or Marrow Transplantation: A Blood or Marrow Transplantation Survivor Study Report Intent   To explore the link between total body irradiation (TBI) and subsequent breast cancer in women treated for hematologic malignancies through blood or marrow transplantation (BMT). PATIENTS AND MAINS Participants were drawn from a retrospective cohort study, the BMT Survivor Study (BMTSS), which included patients…

Jan Schellens, MD, CMO Byondis discusses the Phase I Study of Antibody-Drug Conjugate SYD1875. 11 August 2020, Nijmegen, The Netherlands, Byondis B.V. (formerly Synthon Biopharmaceuticals B.V.) today announced that treatment with its investigational antibody-drug conjugate (ADC) SYD1875 was initiated by the first cancer patients. In patients with 5T4-expressing, locally advanced or metastatic solid tumors, the First-in-Human Dose-Escalation and Expansion Trial with the Antibody-Drug Conjugate SYD1875 will assess the safety, pharmacokinetics, and preliminary efficacy of SYD1875. While 5T4 plays an important role in cancer growth, there are currently no drugs that target this particular tumor antigen. Patients are currently registered at…

Mansoor Raza Mirza, MD from Region Hovedstaden discusses an abstract from ASCO 2020 entitled Final survival analysis of NSGO-AVANOVA2/ENGOT-OV24: Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer—A randomized controlled chemotherapy-free study Background: We previously reported significantly improved progression-free survival (PFS) with the chemotherapy-free regimen of niraparib and bevacizumab compared to niraparib alone, in women with platinum-sensitive relapsed ovarian cancer (PSROC), regardless of homologous recombination deficiency (HRD) status (MyChoice HRD), duration of chemotherapy-free interval (CFI) and number of previous lines of therapy (Mirza MR et al, Lancet Oncol 2019). We now present the updated…

Andreas Burchert, MD University Hospital Giessen and Marburg Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN) Intent — Patients with acute myeloid leukemia ( AML) with internal tandem duplication mutation in the FMS-like tyrosine kinase 3 gene (FLT3-ITD) have a poor prognosis, often relapse, and die as a consequence of AML, despite undergoing allogeneic hematopoietic stem cell transplant (HCT). Whether a maintenance therapy using FLT3 inhibitors, such as the multitargeted tyrosine kinase inhibitor sorafenib, improves outcome after HCT, is currently uncertain. MAINS In a randomized , placebo-controlled, double-blind phase II…

Sepideh Azarianpour-Esfahani, Ph.D. of Case Western Reserve University discusses an abstract from ASCO 2020 Computerized features of spatial arrangement of tumor-infiltrating lymphocytes from H&E images predicts survival and response to checkpoint inhibitors in gynecologic cancers Context: Immune checkpoint inhibitors (ICI) in solid tumors have proved effective. Except for MSI-H endometrial cancer (~ 50 percent), the response rate is still poor in gynecologic cancers (GC) (~10-15 percent). Present biomarkers (e.g., expression of PDL1) have limited usefulness in recognizing ICI benefits in GC. In this research, the ability of H&E slide images to predict overall survival ( OS) and response to ICI…

Nicolo Manaresi, Ph.D. Chief Scientific Officer of M Silicon Biosystems gives an overview of Two Studies Presented at AACR 20 Meeting Deepen Understanding Of Cancer Mechanisms “The products and workflow described in this video are for research use only. Not for use in diagnostics procedures.” BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., Aug. 4, 2020 / PRNewswire/ — The pioneer of liquid biopsy technology, Menarini Silicon Biosystems, today revealed two new studies documenting genetic changes in circulating cancer cells that could enhance cancer prognosis and help guide treatment. Ses studies were presented as posters at the American Association for Cancer Research…

Allison Huegel, COO AxoProtego and Ahmet Hoke, MD, Ph.D. Johns Hopkins Medicine gives an overview of AxoProtego Therapeutics Announces Novel Investigational Agent for Chemotherapy-Induced Peripheral Neuropathy. GLEN BURNIE, Md., July 27, 2020 / PRNewswire/ — AxoProtego Therapeutics (AxoProtego) has announced the licensing of a novel investigational treatment for patients with peripheral neuropathy (CIPN) caused by chemotherapy. There is currently a significant unmet medical need for this life-altering disorder as 30-80 % of patients with cancer experience peripheral neuropathy caused by chemotherapy, whether from conventional chemotherapy, biologics or cell-based therapies. The National Institute of Health (NIH) National Cancer Institute ( NCI)…

John R. “Jack” Steel, M.D. F.A.C.R.O. of Tampa Bay Radiation Oncology discusses Managing Anxiety During Cancer Treatment. Some of the most difficult emotions to handle during cancer treatment can be nausea, apprehension, and panic. Here are some ways to cope with those feelings that will make you feel better. The majority of cancer patients don’t feel nervous all the time. Maybe you’ll feel anxious: Right before therapy Upon care Reflecting on going to the hospital or clinic Going for a check-up Waiting to see the results It helps to explore your own way to deal with your anxieties. Maybe you…

David Spetzler, M.S., Ph.D., MBA, President and Chief Scientific Officer of Caris Life Sciences discusses their Partners with Elevation Oncology to Advance Enrollment in Phase 2 Trial of Patients with Solid Tumors Harboring NRG1 Gene Fusions. IRVING, Texas, Aug. 11, 2020 /PRNewswire/ — Caris Life Sciences ®, a leading molecular science innovator focused on delivering on the promise of precision medicine, today announced it has entered into a strategic alliance with Elevation Oncology to improve patient enrollment procedures for genomically guided, tumor-agnostic clinical trials. Using Caris’ market-leading molecular profiling offerings package, the clinical trial solutions of Caris Pharmatech Just-In-Time (…

Rana R. McKay, MD UC SD Health discusses ASCO 2020 abstract entitled Optimized management of nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma (RCC): A response-based phase II study (OMNIVORE) Context: For advanced RCC, Nivo + Ipi is a proven first-line treatment (tx). We hypothesized that not all patients (pts) would need to have CTLA-4 blockade applied. In addition, Nivo’s optimum maintenance time in response pts is not known. In this phase II response-adaptive trial, we investigate the sequential addition of 2 doses of Ipi in response pts (NCT03203473) to induce response in Nivo non-responders (NR) and duration…

Benoit You, MD, Ph.D. from Centre Hospitalier Lyon-Sud discusses an ASCO 2020 abstract entitled ROPHIMMUN phase II trial, cohort A Context: Patients with monochemotherapy-resistant gestational trophoblastic tumors (GTT) are treated with historical chemotherapy regimens considered to be productive yet toxic. In all GTT subtypes (Bolze et al. Int J Gynecol Cancer 2017), PD-L1 is expressed constitutively. GTT immune-surveillance includes HLA-G and natural killer ( NK) cells. The monoclonal antibody avelumab (Pfizer & Merck KGaA) anti-PD-L1 causes cytotoxicity via NK cells. TROPHIMMUN study aimed to determine the effectiveness of avelumab in patients with chemoresistant GTT. Approaches: In the cohort A of…

Babar Bashir, MD from Jefferson Health discussed an ASCO 2020 abstract entitled BT5528-100 phase I/II study of the safety, pharmacokinetics, and preliminary clinical activity of BT5528 in patients with advanced malignancies associated with EphA2 expression. Context: BT5528 is a Bicycle Toxin Conjugate (BTC), consisting of a tumor antigen EphA2 targeting bicyclic peptide, connected to a cytotoxin (monomethyl auristatin E [MMAE]) through a cleavable tumor microenvironment linker. Bicycles, developed by Bicycle Therapeutics, are a novel class of chemically synthesized restricted peptides. EphA2 is reported to be overexpressed in a number of solid tumors, leading to oncogenesis, angiogenesis associated with tumours, and…

Johanna C. Bendell, MD from Sarah Cannon discusses and ASCO 2020 abstract entitled A phase I/II, two-part, multicenter, first-in-human study of DS-7300a in patients with advanced solid malignant tumors Context: B7 homologue 3 (B7-H3) is a protein that is overexpressed in different forms of cancer, including squamous cell carcinoma of the lung, head and neck, prostate, esophageal, and breast. Overexpression of B7-H3 is related to poor prognosis because it facilitates increased cancer cell invasive and metastatic potential (Dong P, et al. Front Oncol. 2018;8:264). No targeted cancer therapies with B7-H3 are currently approved. DS-7300a is an antibody-drug conjugate made up…

Ramaprasad Srinivasan, M.D., Ph.D. – NIH National Cancer Institute Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer Context:  HLRCC is a type 2 papillary RCC (pRCC) variant-related familial cancer syndrome. HLRCC is caused by the gene for the Krebs cycle enzyme fumarate hydratase (FH) by germline mutations. FH inactivation results in VHL-independent hypoxia-inducible factor upregulation, dependency on aerobic glycolysis, and activation of the NRF2 pathway, characteristics that some sporadic pRCC tumors also share. We hypothesized that the metabolic alterations that underlie…

David A. Braun, MD, PhD from Dana Farber discusses an ASCO 2020 abstract entitled Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade Context: The treatment of many advanced malignancies, including clear cell renal cell carcinoma (ccRCC), has modified immune control point inhibitors targeting the PD-1 pathway, but the PD-1 response drivers and resistors remain incompletely elucidated. In addition, the widespread paradigm in solid tumor immunology that pre-existing infiltration of CD8 + T cells in combination with large numbers of nonsynonymous mutations (which may be viewed as neoantigens in the sense of various HLA class I…

Paola Nix, Ph.D. at Myriad Genetics discusses an ASCO 2020 abstract entitled Functional RNA Studies Are a Useful Tool in Variant Classification but Must Be Used With Caution: A Case Study of One BRCA2 Variant Since it can guide health management and cancer care decisions, the use of genetic testing to determine hereditary cancer risk is growing. In BRCA1 and BRCA2, for instance, pathogenic variants are considered to be associated with inherited breast and ovarian cancer syndrome. In one of these genes, a germline pathogenic variant is associated with an increased cancer risk and thus merits altered medical management, including…

Thanh Hue Dellinger, MD from the City of Hope discusses an ASCO 2020 abstract entitled Whole transcriptome changes correlate to exceptional ovarian cancer responders: A sub-analysis of a HIPEC Phase I trial. Context: Patients with advanced stage ovarian cancer benefit from hyperthermic intraperitoneal chemotherapy (HIPEC), which prolongs their overall survival by almost 12 months. But HIPEC-triggered molecular changes are not well characterized and no molecular response signatures are identified. We studied improvements in early gene expression in ovarian tumors following treatment with HIPEC. Approaches: This is an interval subgroup study of a single Phase I institution trial using HIPEC at…

Patrick Glen Pilie, MD MD Anderson discusses an ASCO 2020 abstract entitled Identifying Functional Loss of ATM Gene In Patients With Advanced Cancer Context: In cancer, ATM is commonly mutated, and defects can serve as a putative predictive biomarker. However, most ATM variants are not well known for their functional effects. In this study , we examined the relationship between ATM variants and ATM protein expression in advanced cancer patients (pts) to better distinguish the ATM functional defects. Approaches: We retrospectively identified pts seen on CLIA-certified next generation sequencing (NGS) assays at MD Anderson Cancer Center that had ATM variants…

Matthew Galsky, MD from Mount Sinai Tisch Cancer discusses an ASCO 2020 abstract entitled Phase III IMvigor 130 Study Tumor, immune, and stromal characteristics associated with clinical outcomes with atezolizumab (atezo) + platinum-based chemotherapy (PBC) or atezo monotherapy (mono) versus PBC in metastatic urothelial cancer (mUC)Context: Clinical outcomes with atezo mono in mUC are associated with tumor mutational burden (TMB), PD-L1 expression, T-effector gene expression (GE) and a fibroblast TGF-β-response signature (F-TBRS) (Mariathasan, Nature, 2018). The possible predictive role of these biomarkers and APOBEC mutagenesis in IMvigor130 is discussed here. Approaches: Pts receiving first-line (1L) treatment with mUC (tx) were…

Eleni Efstathiou, MD, Ph.D. of MD Anderson discusses an ASCO 2020 abstract entitled Neoadjuvant apalutamide (APA) plus leuprolide (LHRHa) with or without abiraterone (AA) in localized high-risk prostate cancer (LHRPC) Context: Novel androgen signaling inhibitors (ASIs) with medical castration could improve LHRPC outcomes. We have previously documented an association of relapse-free survival with pathologic tumor regression steps. However, a broad spectrum of recurrent cancers has been identified. A research investigating the APA effect in LHRPC was conducted to build on our findings and assess candidate outcome predictors. Approaches: This is a 6-month APA+LHRHa + /- AA (randomized 1:1) Phase II…

Ajay Goel, Ph.D. of the City of Hope speaks about the AACR 2020 Abstract 1084: EpiPanGI-Dx: A cell-free DNA methylation fingerprint for the early detection of gastrointestinal cancers.SummaryPurpose: DNA methylation alterations have emerged as front-runners in biomarker development in view of high cancer specificity, especially as cell-free DNA (cf-DNA) biomarkers for early cancer detection. Much effort to date, however, has concentrated on the development of cancer type-specific biomarkers, but the prospect of developing a pan-cancer diagnostic assay has not been explored. In this sense, gastrointestinal ( GI) cancers, including colorectal (CRC), esophageal squamous cell and adenocarcinoma (ESCC and EAC), gastric…

David Spigel, MD at Sarah Cannon discusses an ACCC 2020 presentation entitled Results Show Multidisciplinary Team Approach Needed for Best Care, Outcomes The project was founded in collaboration with the American College of Chest Physicians (CHEST), the International Association for the Study of Lung Cancer (IASLC) and the LUNGevity Foundation, with funding from AstraZeneca. It aims to explore the benefits of care management within a multidisciplinary cancer team, assess and quantify the current awareness by clinicians of emerging criteria for diagnosis and treatment of lung cancer, recognize and address obstacles to improving care, and evaluate process improvement models across a…

Nancy Beatriz Gordon, MD from MD Anderson discusses an abstract from ASCO 2020 entitled A Phase I Trial Of Aerosol Gemcitabine For The Treatment Of Patients With Solid Tumors And Lung Metastases Context: Therapeutic effectiveness has been seen in pre-clinical trials of aerosol gemcitabine (GCB) in mice and dogs with osteosarcoma (OS) lung metastases. In adults with lung cancer, aerosol GCB administered once a week has been shown to be healthy. Direct delivery of GCB through inhalation to the lungs can result in higher concentrations of drugs in the tumor with fewer side effects. In order to determine the viability…

Istvan Petak, MD #ASCO20 Oncompass Medicine SHIVA01 Trial Update Context: Precision oncology demands that individual molecular pathomechanisms be identified in order to find appropriate tailored treatment strategies for each cancer patient. Owing to the lack of a reproducible, systematic method of clinical decision-making, the integration of complex molecular knowledge into routine clinical practice remains a major challenge. Approaches: We are designing a precision oncology decision support system, the Realtime Oncology Molecular Treatment Calculator (MTC), to provide a structured method for molecular analysis. MTC is a medical information engine based on rules that aggregates and ranks applicable science and clinical data dynamically…

Scott Kopetz, MD at MD Anderson discusses the FDA Approval Encorafenib) In Combination With Cetuximab For The Treatment Of Brafv600E-Mutant Metastatic Colorectal C Based on BEACON CRC test results, BRAFTOVI plus cetuximab showed a median overall survival ( OS) of 8.4 months (95 percent CI: 7.5, 11.0) compared to 5.4 months (95 percent CI: 4.8, 6.6) for Control (cetuximab irinotecan or cetuximab FOLFIRI) ([HR 0.60, (95 percent CI: 0.45, 0.79), p=0.0003]). In addition, BRAFTOVI plus cetuximab showed an improved target response rate (ORR) of 20 percent (95 percent CI: 13 percent, 29 percent ) compared to 2 percent (95 percent…

Sonny Hsiao, Ph.D. of Acopedia shares his final thoughts on Acepodia Presents Preclinical Data on its Lead NK Cell Therapy Candidate ACE1702 at 2020 AACR Virtual Meeting II. SAN FRANCISCO and TAIPEI, Taiwan, June 22, 2020 (GLOBE NEWSWIRE) — Acepodia, a biotechnology company developing cancer immunotherapy based on its innovative technology platform ACC (Antibody Cell Conjugation), today revealed preclinical data on ACE1702, a natural killer cell (NK cell) therapy being developed as a treatment for strong HER2-expressing tumours. The knowledge was discussed at the 2020 Virtual Annual Meeting II of the American Association for Cancer Research (AACR) in a digital…

Sonny Hsiao, Ph.D. of Acopedia discusses Acepodia Presents Preclinical Data on its Lead NK Cell Therapy Candidate ACE1702 at 2020 AACR Virtual Meeting II. SAN FRANCISCO and TAIPEI, Taiwan, June 22, 2020 (GLOBE NEWSWIRE) — Acepodia, a biotechnology company developing cancer immunotherapy based on its innovative technology platform ACC (Antibody Cell Conjugation), today revealed preclinical data on ACE1702, a natural killer cell (NK cell) therapy being developed as a treatment for strong HER2-expressing tumours. The knowledge was discussed at the 2020 Virtual Annual Meeting II of the American Association for Cancer Research (AACR) in a digital poster session. ACE1702 is…

Alessandro Santin, MD of Byondis shares his final thoughts on the study: Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine in Advanced Endometrial Cancer NIJMEGEN, The Netherlands, newswire/-Byondis B.V. July 15, 2020 / B3C (formerly Synthon Biopharmaceuticals B.V.) today reported that in its Phase II research evaluating the safety and efficacy of its investigational antibody-drug conjugate (ADC) [vic-]trastuzumab duocarmazine (SYD985) in patients with HER2-expressing recurrent, advanced or metastatic endometrial (uterine) cancer, treatment was initiated in the first patients. A Phase II single-arm trial to evaluate the safety and efficacy of Antibody-Drug Conjugate (ADC) [vic-]trastuzumab duocarmazine (SYD985) in patients…

Alessandro Santin, MD of Byondis talks about what are the next steps for the study: Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine in Advanced Endometrial Cancer NIJMEGEN, The Netherlands, newswire/-Byondis B.V. July 15, 2020 / B3C (formerly Synthon Biopharmaceuticals B.V.) today reported that in its Phase II research evaluating the safety and efficacy of its investigational antibody-drug conjugate (ADC) [vic-]trastuzumab duocarmazine (SYD985) in patients with HER2-expressing recurrent, advanced or metastatic endometrial (uterine) cancer, treatment was initiated in the first patients. A Phase II single-arm trial to evaluate the safety and efficacy of Antibody-Drug Conjugate (ADC) [vic-]trastuzumab duocarmazine…

Alessandro Santin, MD of Byondis speaks about will this affect clinicians today on the study: Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine in Advanced Endometrial Cancer NIJMEGEN, The Netherlands, newswire/-Byondis B.V. July 15, 2020 / B3C (formerly Synthon Biopharmaceuticals B.V.) today reported that in its Phase II research evaluating the safety and efficacy of its investigational antibody-drug conjugate (ADC) [vic-]trastuzumab duocarmazine (SYD985) in patients with HER2-expressing recurrent, advanced or metastatic endometrial (uterine) cancer, treatment was initiated in the first patients. A Phase II single-arm trial to evaluate the safety and efficacy of Antibody-Drug Conjugate (ADC) [vic-]trastuzumab duocarmazine…

Jeff Ross, MD at Foundation Medicine discusses an ASCO 2020 abstract entitled Clinically aggressive malignancies associated with STK11 germline mutations (STK11GCa): A comprehensive genomic profiling (CGP) study Context: Peutz-Jehger ‘s Syndrome and a number with malignancies with variable clinical aggressiveness are associated with germline mutations in the STK11 (LKB1) mTOR pathway gene. Recent evidence also ties inactivation of STK11 to failure to benefit from therapy with anti-cancer immune control point inhibitor (IO) in NSCLC. Approaches: We detected 103 (0.05 percent) STK11GCa inactivating base substitutions or indels using hybrid capture based CGP based on extracted tumor DNA and a reported “somatic-germline-zygosity”…

Theresa Deisher PhD at AVM Biotechnology discusses The WWRD Study: AVM0703 for Treatment of Leukemia or Lymphoma Description in detail: Phase 1 Patients will be included in the Phase 1 segment of the study in a 3 + 3 dose-escalation design to determine dose-limiting toxicity (DLT) and set the Maximum Tolerated Dose (MTD)/Recommended Phase 2 (RP2D). Up to 9 cohorts of the sequential dose AVM0703 are expected. 3 to 6 patients are enrolled in each cohort. After 7 days of evaluation-patient in each cohort is sequentially enrolled. After 3 patients have completed the 21-day DLT evaluation period with no confirmed…

Christian Marsolais @Theratech_ #AACR20 NEW DATA SHOW THERATECHNOLOGIES’ SORT1+ TECHNOLOGY IS EFFECTIVE IN MANY TREATMENT-RESISTANT CANCERS The optimisation of the ability of identified natural cancer agents Science has found many compounds in nature that have the ability to combat cancer. Such compounds, however, are often unstable or need to be taken in amounts that are impractical. Phytochemicals found in plants, such as curcumin, have shown antiproliferative, antiangiogenic, and apoptotic properties against various cancers such as colorectal, ovarian, and breast cancers. However, these phytochemicals have low bioavailability when administered alone and are easily degraded and poorly absorbed through the gastro-intestinal tract.…

Alessandro Santin, MD of Byondis answers common questions on the study: Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine in Advanced Endometrial Cancer. NIJMEGEN, The Netherlands, newswire/-Byondis B.V. July 15, 2020 / B3C (formerly Synthon Biopharmaceuticals B.V.) today reported that in its Phase II research evaluating the safety and efficacy of its investigational antibody-drug conjugate (ADC) [vic-]trastuzumab duocarmazine (SYD985) in patients with HER2-expressing recurrent, advanced or metastatic endometrial (uterine) cancer, treatment was initiated in the first patients. A Phase II single-arm trial to evaluate the safety and efficacy of Antibody-Drug Conjugate (ADC) [vic-]trastuzumab duocarmazine (SYD985) in patients with…

Alessandro Santin, MD of Byondis talks about the study: Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine in Advanced Endometrial Cancer NIJMEGEN, The Netherlands, newswire/-Byondis B.V. July 15, 2020 / B3C (formerly Synthon Biopharmaceuticals B.V.) today reported that in its Phase II research evaluating the safety and efficacy of its investigational antibody-drug conjugate (ADC) [vic-]trastuzumab duocarmazine (SYD985) in patients with HER2-expressing recurrent, advanced or metastatic endometrial (uterine) cancer, treatment was initiated in the first patients. A Phase II single-arm trial to evaluate the safety and efficacy of Antibody-Drug Conjugate (ADC) [vic-]trastuzumab duocarmazine (SYD985) in patients with HER2-Expressing Endometrial Carcinoma…

Ignacio Garrido-Laguna, MD at Huntsman Cancer Institute discusses the ASCO 2020 abstract entitled A phase I, first-in-human, open-label, dose‑escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP‑3654 administered daily for 28 days to patients with advanced solid tumors. Context: TP-3654 is an oral, second-generation, active PIM-1 kinase inhibitor with PIM 2 , 3 activity and positive selectivity against other kinases. These cytoplasmic serine / threonine kinases are highly expressed in many cancers, and their oncogenic ability was primarily due to suppressing downstream apoptosis of stimuli including inflammatory cytokines and other immune effectors. It has also been shown that TP-3654 mediates…

Oliver Peacock, MD The University of Texas MD Anderson Cancer Center gives his final thoughts about his ASCO 2020 Abstract on Improving the AJCC/TNM staging classification for colorectal cancer: The prognostic impact of tumor deposits. Background: Tumor deposit (TD) detection currently plays a limited role in colorectal cancer ( CRC) staging other than for N1c classification. The purpose of this research was to evaluate the prognostic effect of TD among primary CRC patients, beyond the AJCC N1c classification.  Methodology: Patients with stage 1 to 3 primary CRC diagnosed between 2010 and 2015 were reported from the Monitoring, Epidemiology and End…

Oliver Peacock, MD The University of Texas MD Anderson Cancer Center answers common questions he has received for his ASCO 2020 Abstract on Improving the AJCC/TNM staging classification for colorectal cancer: The prognostic impact of tumor deposits.Background:Tumor deposit (TD) detection currently plays a limited role in colorectal cancer ( CRC) staging other than for N1c classification. The purpose of this research was to evaluate the prognostic effect of TD among primary CRC patients, beyond the AJCC N1c classification. Methodology:Patients with stage 1 to 3 primary CRC diagnosed between 2010 and 2015 were reported from the Monitoring, Epidemiology and End Results (SEER)…